Back to top anchor

EGFR Mutation Testing

12 months
Approved budget:
Professor Mark McKeage
Health issue:
Cancer (oncology)
Proposal type:
Epidermal Growth Factor Receptor Project
Lay summary
Lung cancer is a major cause of death in NZ, especially among Maori and Pacific people. The National Health Committee (NHC) recently recognised the potential for addressing these disparities and poor health outcomes by using targeted therapy for selected patients whose lung cancers harbour mutations in the Epidermal Growth Factor Receptor (EGFR) gene. This research will assist NHC in developing its recommendations for EGFR gene mutation testing in NZ by: 1) evaluating the clinical performance of an existing EGFR gene mutation test in a NZ medical laboratory for analysing clinical samples from NZ lung cancer patients; 2) describing the incidence, profile and outcomes of EGFR mutant lung cancer in NZ, and; 3) ascertaining levels of patient access to EGFR gene mutation testing and relevant treatments in NZ. The research findings are also expected to be of interest to healthcare service providers, patient advocacy groups and Cancer Control organisations in NZ.